Rameda Pharmaceuticals
Kareman Ahmed is a dedicated medical student currently associated with the Royal College of Physicians and the University of Edinburgh. With significant experience in the healthcare field, Kareman is an Associate Member of the American Association for Cancer Research and a Research Student at the American Society for Microbiology, focusing on research, workshops, and publications. Additionally, Kareman contributes to the Egyptian Drug Authority as part of the EDA-Pharmaceutical Care Initiative for Pharmacovigilance, engaging in monitoring adverse drug effects. Other roles include membership in Science Land and the Undergraduate Research Initiative, along with trainee positions at Rameda Pharmaceuticals and Mash Premiere. Kareman holds a Bachelor of Pharmacy from Heliopolis University and has completed the Aspire Leaders Program at Aspire Institute, supplemented by education at Harvard Business School.
This person is not in any teams
Rameda Pharmaceuticals
Our Vision: To become the most valuable emerging pharmaceutical company in Egypt. Our Mission: To provide our customers quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements. Establishment Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region. Owners hired V-Konsult of Germany to create a state-of-the art design. Contracted British Carter Construction company to build the Rameda’s facilities. Partnership with Alcon In 1999, Rameda entered into an agreement with Alcon to manufacture – under license - their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda. Quality enhancement Rameda renewed the syrup production to become GMP (Good Manufacturing Practice). A new Beginning In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry. To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team. Company has commissioned M+W Group to transform solid dosage and beta lactam areas into GMP. Brining entire facility to compliance.